Nanocellulose Fiber Raised Fetal Survival to 76% in a Dangerous Pregnancy Liver Condition

Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that can turn a healthy pregnancy fatal, yet the standard drug used to treat it has repeatedly failed to move the needle on fetal outcomes. Now, preliminary research published in Advanced Science suggests that cellulose nanofibers, microscopic strands derived from plant cell walls, may sharply improve both maternal liver function and offspring survival by rewiring the gut microbiome and the bile acid circuits it controls. The findings come from rat experiments and clinical sample comparisons, not human trials, so they represent early but compelling evidence.

What Cellulose Nanofibers Did to ICP Survival Rates

In the study's rat model of ICP, offspring survival sat at just 14% without treatment, and only 17% in animals given ursodeoxycholic acid (UDCA), the current first-line drug. Cellulose nanocrystals (CNC) raised that figure to 57%. But the standout result came from cellulose nanofibers (CNF): pups born to CNF-treated mothers survived at a rate of 76%. CNF was administered at 90 mg/kg per day, starting 14 days before pregnancy, framing it as a prophylactic rather than an acute therapy.

Maternal markers told a similar story. CNF treatment produced the most pronounced reductions in serum total bile acids (TBA) and liver transaminases, and tissue examination showed that the disorganized hepatocyte arrangements, inflammatory infiltration, and hepatic necrosis seen in untreated ICP rats were substantially reversed. Ileal tissue, where bile acids are reabsorbed from the gut, showed comprehensive recovery of villous architecture. Placental inflammation was also attenuated, particularly in CNF-treated animals.

Why ICP Is Such a Difficult Problem for Pregnant Women

ICP, the most common liver disorder specific to pregnancy, is defined by pruritus and a surge in serum bile acids that can reach levels toxic to the fetal heart and liver. A systematic review and meta-analysis has linked it to increased rates of preterm birth, cesarean delivery, and neonatal intensive care unit admission; the study in Advanced Science notes it affects up to 15% of pregnancies globally, with severe cases carrying a real risk of intrauterine death.

UDCA became the default treatment because it reduces maternal itch and lowers serum bile acids to some degree, but its ability to meaningfully improve perinatal outcomes has been challenged by recent trials. That gap between maternal symptom relief and fetal protection is precisely the space this research tries to address.

How Gut Microbiota Drive Bile Acid Overload in ICP

Bile acids are not simply produced by the liver; they are extensively reprocessed by gut bacteria. Research has shown that altered intestinal microbiota during pregnancy can impair the enterohepatic feedback that normally keeps bile acid synthesis in check, contributing to the bile acid accumulation that defines ICP. A separate Nature Communications study confirmed that gut microbiota directly alter host bile acid metabolism in ICP development, with bile salt hydrolase (BSH)-producing bacteria playing a central role.

In the new work, ICP rats showed enrichment of Spirochaetota and Treponema, bacteria associated with secondary bile acid production through a process called 7-alpha-dehydroxylation. CNF treatment suppressed this conversion, leading to higher fecal excretion of primary bile acids (cholic acid and chenodeoxycholic acid) rather than their more toxic secondary derivatives. Stool from CNF-treated rats was also richer in beneficial taxa from the Prevotellaceae family, including Alloprevotella, which correlated with lower serum TBA and liver enzyme levels.

To confirm that the microbiome shift was driving the benefit, the researchers performed fecal microbiota transplantation (FMT): transferring stool from CNF-treated donors into ICP recipient rats was sufficient, on its own, to reduce ICP disease markers. That experiment is one of the study's stronger methodological moves, because it isolates the microbial contribution from any direct chemical action of the fiber itself.

The FXR Signaling Pathway That Links Fiber to Fetal Protection

The gut-liver bile acid circuit runs through a nuclear receptor called farnesoid X receptor (FXR). When bile acids activate FXR in the intestinal wall, it triggers a hormonal signal, fibroblast growth factor 15 (FGF15) in rodents, FGF19 in humans, that travels to the liver and suppresses the rate-limiting enzyme of bile acid synthesis, CYP7A1. ICP rats showed lower intestinal FXR activity and reduced circulating FGF15, meaning that brake on bile acid production was partially disengaged.

CNF treatment restored FXR, FGF15, and a downstream suppressor gene (Shp) in both the ileum and liver, while CYP7A1 expression fell back toward normal. The transporter that pumps bile acids out of liver cells, MRP2, was also significantly elevated in CNF-treated animals, suggesting enhanced excretion as an additional protective mechanism. When the researchers blocked FXR directly using the antagonist Z-guggulsterone, all of CNF's benefits, including the fetal survival gains, were abolished, providing causal evidence that FXR signaling is not merely a correlate but the functional mechanism.

CNF also reshaped the broader metabolome. Short-chain fatty acids (acetic, butyric, propionic) and tryptophan-derived metabolites increased in the feces of treated animals, while serum and liver showed elevated TCA cycle intermediates, consistent with improved mitochondrial energy metabolism. These metabolite shifts likely reflect the broader ecosystem change in the gut rather than a single targeted intervention.

Open Questions Before Nanocellulose Reaches a Clinic

The study's authors are candid about what remains unknown. The rat model was induced chemically using ethinylestradiol (EE2), and species-specific differences may limit how directly the results translate to human pregnancies. Clinical trials have not yet been conducted. The optimal timing and human-equivalent dose for prophylactic CNF administration still need to be defined through pharmacokinetic studies. The contribution of CNF's physical adsorption capacity, its ability to simply bind bile acids in the gut lumen before they can be reabsorbed, was not fully separated from its microbiome-remodeling effects. Biodistribution of the nanofibers and their potential accumulation in fetal organs were not directly quantified.

On the safety side, the study found no cytotoxicity or adverse effects in either non-pregnant or pregnant rats across the treatment periods evaluated, and nanocellulose materials have been broadly characterized as biocompatible in biomedical research contexts. But what is safe in an eight-week rodent study will need rigorous human pharmacovigilance before any clinical application. For now, the picture is striking enough as proof of concept: a dietary fiber, reshaped into nanoscale strands, may be capable of recruiting the gut microbiome as a therapeutic ally in one of pregnancy's most stubborn liver conditions.

Evidence rating

INVESTIGATIONAL — 78/100

Caveats:

• This study was conducted in rats using a chemically induced model of ICP — results have not yet been tested in human clinical trials.
• Funding was not disclosed in the article, so independent replication of these findings is important before drawing firm conclusions.
• The prophylactic dosing window and human-equivalent dose of CNF have not been established.
• Nanocellulose biodistribution and fetal organ safety were not directly measured in this study.

Preclinical rat model study with supporting in vitro validation and a small clinical correlate sample. Demonstrates mechanistic specificity — named microbial taxa, bile acid pathways, and FXR signaling — but causation in humans has not been established. Not yet replicated in an independent animal cohort or human trial.